Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib
Keyword(s):
2007 ◽
Vol 176
(2)
◽
pp. 93-99
◽
Keyword(s):
2018 ◽
Keyword(s):